Taking pravastatin for 3 months didn't harm the transplanted kidney's ability to work in patients without diabetes.
Scientific Claim
Pravastatin at 40 mg/day for 12 weeks does not impair kidney graft function in non-diabetic kidney transplant recipients, as graft function remained stable throughout the trial.
Original Statement
“Kidney graft function remained stable throughout the trial for all patients.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The statement is descriptive and lacks quantitative metrics (e.g., eGFR change), but the abstract does not overstate. Given the RCT design and lack of reported decline, the claim is appropriately framed as neutral observation.
More Accurate Statement
“Pravastatin at 40 mg/day for 12 weeks may not impair kidney graft function in non-diabetic kidney transplant recipients, as graft function remained stable throughout the trial.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bIn EvidenceWhether pravastatin causes no clinically significant change in kidney function (e.g., eGFR, serum creatinine) in transplant recipients.
Whether pravastatin causes no clinically significant change in kidney function (e.g., eGFR, serum creatinine) in transplant recipients.
What This Would Prove
Whether pravastatin causes no clinically significant change in kidney function (e.g., eGFR, serum creatinine) in transplant recipients.
Ideal Study Design
Double-blind RCT with 200+ non-diabetic kidney transplant recipients, randomized to pravastatin 40 mg/day vs. placebo for 12 months, with primary endpoint being change in estimated GFR from baseline, and secondary endpoints including serum creatinine, proteinuria, and biopsy-proven rejection.
Limitation: Cannot detect very rare or very slow graft injury over decades.
Prospective Cohort StudyLevel 2bWhether long-term pravastatin use is associated with slower decline in graft function in real-world settings.
Whether long-term pravastatin use is associated with slower decline in graft function in real-world settings.
What This Would Prove
Whether long-term pravastatin use is associated with slower decline in graft function in real-world settings.
Ideal Study Design
Prospective cohort of 500+ kidney transplant recipients followed for 5 years, comparing annual eGFR decline rates between those prescribed pravastatin vs. other statins or no statin, adjusting for age, rejection history, and immunosuppression.
Limitation: Cannot prove causation due to confounding by indication and adherence.
Systematic Review & Meta-AnalysisLevel 1aWhether pravastatin has a consistent neutral effect on graft survival and function across multiple studies.
Whether pravastatin has a consistent neutral effect on graft survival and function across multiple studies.
What This Would Prove
Whether pravastatin has a consistent neutral effect on graft survival and function across multiple studies.
Ideal Study Design
Meta-analysis of all RCTs and prospective cohort studies reporting eGFR or graft survival in kidney transplant recipients on pravastatin vs. control, with pooled mean differences in eGFR slope and hazard ratios for graft loss.
Limitation: Cannot assess individual patient risk or rare adverse events.
Evidence from Studies
Supporting (1)
This study gave kidney transplant patients 40 mg of pravastatin daily for 12 weeks and checked if their new kidney kept working well — and it did. So yes, the drug didn’t harm their kidney function.